Multiple-Ascending Dose Study in Healthy Subjects to Assess the Pharmacokinetics, Tolerability, and CYP3A4 Interaction Potential of the T-Type Calcium Channel Blocker ACT-709478, A Potential New Antiepileptic Drug.
Background: ACT-709478 is a selective, orally available T-type calcium channel blocker being studied as a potential new treatment in epilepsy. ACT-709478 had previously been investigated in a single-ascending dose study up to a dose of 400 mg.Objectives: The aim of this study was to investigate the...
| Published in: | CNS Drugs Vol. 34; no. 3; pp. 311 - 324 |
|---|---|
| Main Authors: | , , , , |
| Format: | research Journal Article |
| Published: |
Springer Nature
Mar2020
|
| Online Access: | View this record in EBSCOhost |